Abstract Library

#1417 Everolimus (EVE) Safety Profile in Patients (pts) with Advanced G1-G2 Neuroendocrine Tumours (NETs) from Daily Clinical Practice

Introduction: EVE has shown an overall favourable and well-characterized safety profile in randomized studies including advanced G1-G2 NETs. However, few data outside regulatory trials are available.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Carmona-Bayonas A

Authors: Carmona-Bayonas A, Jiménez-Munarriz B, Jimenez-Fonseca P, Custodio A, Alonso V,

Keywords: everolimus,tolerability,

#1413 Everolimus (EVE) Treatment for Advanced G1-G2 Neuroendocrine Tumours (NETs) in the Community Setting: Clinical Benefit Irrespective of Previous Therapies

Introduction: Randomized studies have shown EVE has antitumour activity in advanced G1-G2 NETs. However, data outside regulatory trials are limited.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Custodio A

Authors: Custodio A, Alonso V, Jimenez-Fonseca P, Lopez C, Alonso T,

Keywords: everolimus, previous therapies,

#568 Efficacy of Everolimus and Tolerability with Long-Term Use

Introduction: Predictors of response to Everolimus in neuroendocrine tumors and long-term safety data are lacking.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Heetfeld M, Tischer E, Denecke T, Perez Fernandez C, Wiedenmann B,

Keywords: everolimus, prior therapies, pneumonitis ,